| Dr Nick Regis Mastrine, PHARMD | |
|
2500 Boulevard Of The Generals, Norristown, PA 19403-3692 | |
| (610) 539-5093 | |
| (610) 539-5294 |
| Full Name | Dr Nick Regis Mastrine |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 2500 Boulevard Of The Generals, Norristown, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083928667 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RP443954 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nick Regis Mastrine, PHARMD 2 Stallion Cir, Horsham, PA 19044-1119 Ph: (814) 248-8079 | Dr Nick Regis Mastrine, PHARMD 2500 Boulevard Of The Generals, Norristown, PA 19403-3692 Ph: (610) 539-5093 |
News Archive
With the advent of personalised medicine, gains in cancer survival over the long term could be improved by running smaller, faster trials with less stringent evidence criteria, a researcher told the 2011 European Multidisciplinary Cancer Congress.
Differences in circadian blood pressure variation due to a combination of genetic and cultural factors may contribute to ethnic differences in cardiovascular morbidity, according to new research from Binghamton University, State University of New York.
Results of an all-Canadian study announced June 13 at an international diabetes congress demonstrate that patients with type 2 diabetes can safely achieve target blood sugar (glycemic) levels faster and more frequently when insulin glargine (a basal, long-acting insulin) is added to therapy, versus using oral agents alone.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.
S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.
› Verified 4 days ago
John Taek Lee, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 699 W Germantown Pike, Norristown, PA 19403 Phone: 610-630-5819 | |
Kathryn Ching, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 80 W Germantown Pike, Norristown, PA 19401 Phone: 610-279-6575 | |
Paul Cianfichi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 Sterigere St, Norristown, PA 19401 Phone: 610-313-5864 | |
Vimala An, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 25 W Germantown Pike, Norristown, PA 19401 Phone: 610-278-0256 Fax: 610-278-4821 | |
Mr. David Lee, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2550 Eisenhower Ave, Norristown, PA 19403 Phone: 484-690-0160 | |
Daniel Desch, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2500 Boulevard Of The Generals, Norristown, PA 19403 Phone: 610-539-5093 |